ECOR1 CAPITAL
EcoR1 Capital is a biotech-focused investment advisory firm.
ECOR1 CAPITAL
Social Links:
Industry:
Biotechnology Financial Services
Founded:
2012-01-01
Status:
Active
Contact:
415-754-3517
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics
Similar Organizations
BioMedPartners
BioMedPartners is one of the leading European venture capital firms.
gumi Cryptos Capital (gCC)
gumi Cryptos Capital is a blockchain and cryptographic asset venture fund
Logos Capital
Logos Capital is a fundamental biotechnology-focused investment fund.
LYFE Capital
LYFE Capital is a life science investment firm.
Polaris Partners
Polaris Partners invests in healthcare and technology companies ​across all stages from founding to profitable growth.
RA Capital Management
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Refactor Capital
Refactor Capital is a seed stage VC firm investing in bio, climate, and health.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-09-07 | SpringWorks Therapeutics | EcoR1 Capital investment in Post-IPO Equity - SpringWorks Therapeutics | 225 M USD |
| 2022-08-25 | Aktis Oncology | EcoR1 Capital investment in Series A - Aktis Oncology | 84 M USD |
| 2022-08-19 | Kymera Therapeutics | EcoR1 Capital investment in Post-IPO Equity - Kymera Therapeutics | 150 M USD |
| 2022-07-27 | AlloVir | EcoR1 Capital investment in Post-IPO Equity - AlloVir | 126.6 M USD |
| 2022-07-13 | Gossamer Bio | EcoR1 Capital investment in Post-IPO Equity - Gossamer Bio | 120 M USD |
| 2022-04-27 | Tempest Therapeutics | EcoR1 Capital investment in Post-IPO Equity - Tempest Therapeutics | 15 M USD |
| 2022-03-16 | 2seventy bio | EcoR1 Capital investment in Post-IPO Equity - 2seventy bio | 170 M USD |
| 2022-02-03 | Dewpoint Therapeutics | EcoR1 Capital investment in Series C - Dewpoint Therapeutics | 150 M USD |
| 2022-01-06 | Eikon Therapeutics | EcoR1 Capital investment in Series B - Eikon Therapeutics | 518 M USD |
| 2021-12-27 | Pardes Biosciences | EcoR1 Capital investment in Post-IPO Equity - Pardes Biosciences | 75 M USD |